Our results, based on a broad range of in vivo models, provide the basis for an additional hypothesis, indicating that a mesenchymal tumor phenotype may represent a necessary, although possibly not sufficient, prerequisite for benefit from FAK inhibition. Here, PTK2 is linked to neoplasm.